Schizophrenia Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Schizophrenia stocks.

Schizophrenia Stocks Recent News

Date Stock Title
Oct 1 LLY U.S. port strike expected to have limited impact on healthcare supply chain: HHS
Oct 1 BMY PRME Stock Rises 11.8% on Collaboration With Bristol Myers
Oct 1 LLY Here's how AI is set to disrupt healthcare — albeit slowly
Oct 1 BMY A schizophrenia win for BMS’ Cobenfy, but challenges lie ahead
Oct 1 LLY t:slim X2's Compatibility With Lilly's Lyumjev Might Aid TNDM Stock
Oct 1 LLY Market Chatter: Eli Lilly Mulls Testing Weight-Loss Drugs on People With Normal Weight
Oct 1 AZN AstraZeneca's Enhertu sBLA Gets FDA Priority Tag for Expanded Use
Oct 1 LLY Lilly looking to test Zepbound as health maintenance drug: report
Oct 1 LLY Roche Ramps Up Breast Cancer Pipeline With Regor's CDK Inhibitors
Oct 1 AZN AstraZeneca's Enhertu application accepted by FDA with priority review
Oct 1 BMY BMS and Prime ink potential $3.5bn deal to develop T cell therapies
Oct 1 LLY Eli Lilly Aims To Expand Weight-Loss Drug Trials To Those At Risk, Not Just Overweight
Oct 1 BMY Read This Before Considering Bristol-Myers Squibb Company (NYSE:BMY) For Its Upcoming US$0.60 Dividend
Oct 1 AZN ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
Oct 1 AZN 5 FDA decisions to watch in the fourth quarter
Oct 1 BMY 5 FDA decisions to watch in the fourth quarter
Oct 1 BMY Bristol-Myers Squibb Company (BMY) is Driving Growth Through Strategic Acquisitions
Sep 30 LLY Tradepulse Power Inflow Alert: Eli Lilly And Company Climbs 15 Points
Sep 30 BMY Bristol Myers gets $6.4B Celgene CVR case dismissed: report
Sep 30 BMY Sector Update: Health Care Stocks Advance Late Afternoon
Schizophrenia

Schizophrenia is a mental disorder characterized by abnormal behavior, strange speech and a decreased ability to understand reality. Other symptoms include false beliefs, unclear or confused thinking, hearing voices that do not exist, reduced social engagement and emotional expression and lack of motivation. People with schizophrenia often have additional mental health problems such as anxiety, depressive or substance-use disorders. Symptoms typically come on gradually, begin in young adulthood and in many cases never resolve.The causes of schizophrenia include environmental and genetic factors. Possible environmental factors include being raised in a city, cannabis use during adolescence, certain infections, the age of a person's parents, and poor nutrition during pregnancy. Genetic factors include a variety of common and rare genetic variants. Diagnosis is based on observed behavior, the person's reported experiences and reports of others familiar with the person. During diagnosis, a person's culture must also be taken into account. As of 2013, there is no objective test. Schizophrenia does not imply a "split personality" or dissociative identity disorder, conditions with which it is often confused in public perception.The mainstay of treatment is antipsychotic medication, along with counselling, job training and social rehabilitation. It is unclear whether typical or atypical antipsychotics are better. In those who do not improve with other antipsychotics, clozapine may be tried. In more serious situations where there is risk to self or others, involuntary hospitalization may be necessary, although hospital stays are now shorter and less frequent than they once were.About 0.3% to 0.7% of people are affected by schizophrenia during their lifetimes. In 2013, there were an estimated 23.6 million cases globally. Males are more often affected and on average experience more severe symptoms. About 20% of people eventually do well, and a few recover completely; about 50% have lifelong impairment. Social problems, such as long-term unemployment, poverty and homelessness, are common. The average life expectancy of people with the disorder is 10–25 years less than that of the general population. This is the result of increased physical health problems and a higher suicide rate (about 5%). In 2015, an estimated 17,000 people worldwide died from behavior related to, or caused by, schizophrenia.

Browse All Tags